Nexium Control 28 Tablet Pack
- One tablet per day
- Maximum 14 consecutive days use
- If symptoms do not resolve or get worse after 14 days refer to a GP
*Should symptoms recur after 3 months, patients may restart a further treatment course. If less than three months after previous treatment, it is advisory to refer patients to seek advice from a GP1
- Ask patients how often they suffer – more than once a week is classed as frequent heartburn
- Patients with frequent heartburn may benefit from a PPI such as Nexium Control to give the oesophagus a ‘holiday’ from acid and reduce sensitivity
Learn more about the role of frequency in heartburn treatment recommendations.
Nexium Control 28 tablet pack
For patients with recurrent frequent heartburn who have used esomeprazole successfully and seek the value and convenience of a larger pack.
Nexium Control 7 and 14 tablet packs
Nexium Control 7 tablet pack is an ideal trial pack with one-week supply. Nexium Control 14 tablet pack offers the same protection and offers a 2-week treatment course.
Nexium Control 14 Capsule pack
Easy-to swallow mini capsules – 53% smaller than tablet* in a portable bottle. Complete 14-day treatment course.
*based on volume
Product Information: Please consult the Summary of Product Characteristics for full product information. Nexium Control 20 mg gastro resistant tablets and hard capsules (esomeprazole). Indications: The short term treatment of reflux symptoms (e.g. heartburn and acid regurgitation) in adults. Dosage: The recommended dose is 20 mg esomeprazole (one tablet or capsule) per day. Tablets or capsules may need to be taken for 2-3 consecutive days to achieve symptom improvement. Maximum treatment duration: up to 2 weeks. Contraindications: Hypersensitivity to the active substance, substituted benzimidazoles or to any of the excipients. Esomeprazole must not be used concomitantly with nelfinavir. Precautions: Refer to doctor if patient has: Jaundice or severe liver disease, unintentional weight loss, recurrent vomiting, dysphagia, haematemesis or melaena and when gastric ulcer is suspected or present, malignancy should be excluded as treatment with esomeprazole may alleviate symptoms and delay diagnosis, gastric ulcer or gastrointestinal surgery, continuous treatment of indigestion or heartburn for 4 or more weeks, or is over 55 years old with new or recently changed symptoms. Not suitable for long term use. Treatment with proton pump inhibitors (PPIs) may lead to a slightly increased risk of gastrointestinal infections such as Salmonella and Campylobacter and in hospitalised patients, also possibly Clostridium difficile. Consult doctor prior to have an endoscopy or urea breath test. Co administration with atazanavir is not recommended. Interactions with medicinal products metabolised through CYP2C19 should be considered. The use of esomeprazole with clopidogrel should be discouraged. Patients should not take another PPI or H2 antagonist concomitantly. PPI are associated with very infrequent cases of SCLE. If lesions occur, especially in sun-exposed areas of the skin, and if accompanied by arthralgia, the patient should seek medical help promptly. Side effects: Common: headache, abdominal pain, constipation, diarrhoea, flatulence, nausea/ vomiting, fundic gland polyps (benign). Uncommon: peripheral oedema, insomnia, dizziness, paraesthesia, somnolence, vertigo, dry mouth, increased liver enzymes, dermatitis, pruritus, rash urticaria. For rare, very rare and other side effects please refer to the SPC for full information. Legal category: Supply through pharmacy only. Product licence number: EU/1/13/860/001; EU/1/13/860/002; EU/1/13/860/003; EU/1/13/860/004 and EU/1/13/860/005. MAH: GlaxoSmithKline Dungarvan Limited, Knockbrack, Dungarvan, County Waterford, Ireland. Additional information is available upon request. Text prepared: June 2022.
Contains esomeprazole. Always read the label/leaflet.